Global Anticoagulant Effects of a Synthetic Anti-Factor Xa Inhibitor (DX-9065a): Implications for Interventional Use

Abstract

Heparin has been conventionally used as an anticoagulant for medical and surgical indications. Because factor Xa is an essential component of the prothrombinase complex and leads to the generation of thrombin, its inhibition has become a focus of newer antithrombotic drug development. The in vitro anticoagulant profile of DX-9065a, a synthetic direct factor Xa inhibitor, was studied using activated clotting time assay, thrombelastography, and global clotting tests, such as prothrombin time (PT), activated partial thromboplastin time (aPTT), diluted aPTT, Heptest, Heptest-HI, dilute Russell's viper venom time (dRVVIT), thrombin time, ecarin clotting time, and amidolytic anti-Xa assay. In addition, the effect of DX-9065a on platelet aggregation and inhibition of thrombin generation markers (FPA, Fl + 2, and TAT) were studied. The pharmacokinetic and pharmacodynamic profiles of DX-9065a were also studied in a non-human primate (Macaca mulatta) model. DX-9065a produced a concentration-dependent increase in the Hemochron celite ACT and HemoTec ACT. Clotting times of 538 ± 19 and 401 ± 12, respectively, were reached at a concentration of 25 μg/mL signifying that DX-9065a may be useful in interventional cardiological procedures. DX-9065a prolonged the r-time on thrombelastography. DX-9065a did not show any effect on adenosine diphosphate (ADP)-, collagen-, epinephrine-, and arachidonic acid-induced platelet aggregation at concentrations up to 10 μg/mL. DX-9065a exhibited a concentration-dependent prolongation of the PT, aPTT, diluted aPTT, Heptest, dRVVT, and reached the clotting times of 51.6, 132, 193, 47.9, 129.9 seconds, respectively, at a final concentration of 12.5,tg/mL; compared to a control value of 10.6, 30.2, 41.9, 14, 32.2 seconds, respectively. DX9065a did not affect the ecarin clotting time and thrombin time at concentrations up to 12.5 μg/mL. Because DX-9065a prolonged the dRVVT, this may impact diagnostic screening of patients with systemic lupus erythematosus.

Keywords

Factor Xa inhibitor Clot-based assays Amidolytic anti-Xa assay Thrombin generation markers Platelet aggregation Pharmacokinetics

References

1. Fareed J , Walenga JM , Hoppensteadt DA , Kaiser B , Jeske W . Factor Xa inhibitors in the control of thrombogenesis. Hamostaseologie 1999;19:55-55.

2. Herault JP , Bernat A , Pflieger AM , Lormeau JC , Herbert JM . Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase. J Pharmacol Exp Ther 1997;283:16-16.

3. Turpie AGG , Gallus AS , Hoek JA . A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001;44(9):619-619.

4. Eriksson BI , Kenneth AB , Lassen MR , Turpie AGG . Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001;345(18):1298-1298.

5. Rai R , Sprengeler PA , Elrod KC , Young WB . Perspectives on factor Xa inhibition. Curr Med Chem 2001;8:101-101.

6. Hara T , Yokoyama A , Ishihara H , Yokoyama Y , Nagahara T , Iwamoto M . DVX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb Haemost 1994;71(3):314-314.

7. Kunidata S , Nagahara T , Hara T . Inhibitors of factor Xa. Curr Pharmaceut Design 1996;2:531-531.

8. Kaiser B , Paintz M , Scholz O , Kunidata S , Fareed J . A synthetic inhibitor of factor Xa, DX-9065a, reduces proliferation of vascular smooth muscle cells in vivo in rats. Thromb Res 2000;98:175-175.

9. Nagahara T , Katakura S , Inamura K , Komoriya S , Hara T , Kunidata S , Yokoyama Y , Yamazaki K , Iwamoto M . Anticoagulant factor Xa inhibitor, DX-9065a. Drugs Future 1995;20(6):564-564.

10.

10. Yamazaki M . Factor Xa inhibitors. Drugs Future 1995;20 (9):911-911.

11.

11. Herbert JM , Bernat A , Dol F , Herault JP , Crepon B , Lormeau JC . DX-9065a, a novel, synthetic, selective and orally active inhibitor of factor Xa: In vitro and in vivo studies. J Pharm Exp Ther 1996:1030-1030.

12.

12. Yamazaki M , Asakura H , Aoshima K , Saito M , Jokaji H , Uotani C , Kumabashiri I , Morishita E , Ikeda T , Matsuda T . Protective effects of DX-9065a, an orally active, novel synthesized and selective inhibitor of factor Xa, against thromboplastin-induced experimental disseminated intravascular coagulation in rats. Semin Thromb Hemost 1996;22:255-255.

13.

13. Yokohama T , Kelly AB , Marzec UM , Hanson SR , Kunidata S , Harker LA . Antithrombotic effects of orally active synthetic antagonist of activated factor Xa in nonhuman primates. Circulation 1995;92:485-485.

14.

14. Murayama N , Sudo K . High-performance liquid chromatographic method for determination of DX-9065a, a novel anticoagulant, in human urine and feces using cation-exchange solid-phase extraction. J Chromatog 1997;692:389-389.